About Vicapsys Life Sciences Inc
- Industry: Biotechnology
- Exchange: OTC MARKETS
- Country: US
- Website: https://vicapsys.com
Frequently Asked Questions
What is the 52-week range for VICP?
The 52-week high is $1.77 and the 52-week low is $0.15.
What is the P/E ratio for VICP?
The P/E ratio data is currently unavailable.
What is the dividend yield for VICP?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
ROE data is currently unavailable.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
P/B ratio data is currently unavailable.
Latest VICP News
Vicapsys Life Sciences Announces Advisory Board Following Completion of Stateline Merger
(OTC PINK:VICP) ("VICP" or the "Company") today announced the members of its Advisory Board, formed following the completion of the Company's reverse merger with of Puerto Rico, Inc. ("Stateline") on September 3, 2026.
RETRANSMISSION: Vicapsys Life Sciences Completes Reverse Merger with Stateline Distributors of Puerto Rico and Signs Definitive Agreement to Acquire NitroMist(R), Creating a Vertically Integrated Pharmaceutical Manufacturing and Distribution Platform Serving Federal, Tribal and Underserved Markets
(OTC PINK:VICP) ("VICP" or the "Company") today announced that it has completed its reverse merger with of Puerto Rico, Inc. ("Stateline"), effective September 3, 2026, and has entered into a definitive asset purchase agreement to acquire the FDA-approved NitroMist® (nitroglycerin) lingual aerosol product.
Vicapsys Life Sciences Completes Reverse Merger with Stateline Distributors of Puerto Rico and Signs Definitive Agreement to Acquire NitroMist(R), Creating a Vertically Integrated Pharmaceutical Manufacturing and Distribution Platform Serving Federal, Tribal and Underserved Markets
(OTC PINK:VICP) ("VICP" or the "Company") today announced that it has completed its reverse merger with of Puerto Rico, Inc. ("Stateline"), effective September 3, 2026, and has entered into a definitive asset purchase agreement to acquire the FDA-approved NitroMist® (nitroglycerin) lingual aerosol product.